title: Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells.
abstract: This study was performed to observe the effect of the combination of nimotuzumab with radiation or gemcitabine-based chemoradiation on antipancreatic cancer cell therapy. Pancreatic cancer cells (PANC-1) were treated with nimotuzumab alone or combined with radiation (2, 4, or 8 Gy), which was either with or without gemcitabine chemotherapy. Cell proliferation, cell cycle distribution, and apoptosis were observed. The inhibition rate, the percentage of G2/M phase arrest, and the apoptosis rate of the combined nimotuzumab with radiation group was significantly higher than the group without nimotuzumab (P < .001). The inhibition rate, the percentage of G2/M phase, and the apoptosis rate of the nimotuzumab therapy combined with gemcitabine-based chemoradiation group were obviously higher than that in gemcitabine-based chemoradiation group (P < .001). In conclusion, nimotuzumab could enhance the anticancer effect of radiation and gemcitabine-based chemoradiation in PANC-1 cancer cells because of the enhancement of cell cycle arrest and apoptosis.
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: Chunzi
authors.initials: C
authors.lastname: Gao
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China The Comprehensive Special Needs Department, the Tumor Hospital of Shanxi Province, Taiyuan, China.
authors.forename: Xianzhen
authors.initials: X
authors.lastname: Wu
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China Oncology Department, the First Hospital of Harbin City, Harbin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Yan
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: Lingnan
authors.initials: L
authors.lastname: Meng
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Shan
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.affiliation: The Second Ward of Oncology Department, the First affiliated Hospital of Harbin Medical University, Harbin, China yzy_mse@163.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Han
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000528:radiation effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects* / Q000528:radiation effects; D059248:Chemoradiotherapy / Q000379:methods*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D010190:Pancreatic Neoplasms / Q000473:pathology*; D000093542:Gemcitabine
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; C501466:nimotuzumab; D000093542:Gemcitabine
keywords: apoptosis; cell cycle; chemoradiation; epidermal growth factor receptor; gemcitabine; nimotuzumab; radiation